Dynavax


Dynavax (DVAX) Stock Is Undervalued with 88% Upside Potential, Says Cowen

Cowen analyst Phil Nadeau is out with a research note on shares of Dynavax (NASDAQ:DVAX) following updates presented at the American Society of Clinical Oncology (ASCO) …

Biotech Talk: Cowen Shares Thoughts on Dynavax (DVAX) Following Favorable Data in Advanced Head and Neck Cancer

Cowen’s Phil Nadeau sings the praises of this “undervalued” biotech stock, encouraged to see DVAX’s cancer drug SD-101 revealed well tolerated results in a mid-stage trial.

Dynavax Technologies (DVAX) Poses Bullish Risk/Reward into Upcoming SD-101 Data

Brian Abrahams believes there could be between 20% to 30% in upside potential waiting in the wings for DVAX shares.

Dynavax Technologies Corporation (DVAX) Draws a Price Target Hike on Back of Big Short-Term Upside Prospects

Cantor’s Elemer Piros bets on 52% upside potential for DVAX stock following its 2017 performance.

Dynavax Technologies Corporation (DVAX) Announces the Launch of HEPLISAV-B in the US

Dynavax Technologies Corporation (NASDAQ:DVAX) announced that HEPLISAV-B™ (Hepatitis B Vaccine) for the prevention of hepatitis B in adults is now available for prescription in the …

Dynavax Technologies Corporation (DVAX) Is Looking at a “Long Commercial Life” Ahead for Its Just-Approved Hepatitis B Vaccine

Cowen believes Dynavax has an asset on its hands that fulfills a valuable unmet need.

Dynavax Technologies Corporation’s (DVAX) Hepatitis B Vaccine Wins FDA Approval

Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S.

Dynavax Technologies Corporation (DVAX) Announces Dosing of First Subject in Phase 1b Study of DV281

Dynavax Technologies Corporation (NASDAQ:DVAX) announced initiation of dosing in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts